Arbele Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$10M
- Investors
-
4
Arbele General Information
Description
Operator of a biotechnology and biopharmaceutical company intended to develop advanced cancer therapies, including immunotherapies, multispecific antibody platforms, and targeted drug conjugates, with emphasis on gastrointestinal and solid-tumor cancers. The company offers advanced data analysis capabilities to cure GI cancers (colon, stomach, pancreas, liver, and esophagus) for the development of targeted therapies that improve patient outcomes and quality of life, enabling businesses to identify anomalies, bugs, and malicious events, enhancing operational efficiency.
Contact Information
Website
www.arbelebio.comCorporate Office
- 12011 Bel-Red Road
- Suite 201
- Bellevue, WA 98005
- United States
Corporate Office
- 12011 Bel-Red Road
- Suite 201
- Bellevue, WA 98005
- United States
Arbele Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | $10M | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 04-Dec-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 07-Apr-2021 | $3M | $129K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 01-Jan-2021 | $129K | $129K | Completed | Clinical Trials - Phase 1 |
Arbele Comparisons
Industry
Financing
Details
Arbele Competitors (4)
One of Arbele’s 4 competitors is TORL BioTherapeutics, a Venture Capital-Backed company based in Culver City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TORL BioTherapeutics | Venture Capital-Backed | Culver City, CA | ||||
| Chimeric Therapeutics | Formerly VC-backed | Carlton, Australia | ||||
| Simcere | Private Equity-Backed | Nanjing, China | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany |
Arbele Patents
Arbele Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026060187-A1 | Multispecific antibody-drug conjugates (adc) targeting cdh17-expressing tumors and method of making and using thereof | Pending | 11-Sep-2024 | ||
| US-20260309708-A1 | Compositions and methods for determining the effects of t cell engager | Pending | 17-Apr-2023 | ||
| WO-2024220437-A2 | Compositions and methods for determining the effects of t cell engager | Inactive | 17-Apr-2023 | ||
| WO-2024220437-A3 | Compositions and methods for determining the effects of t cell engager | Inactive | 17-Apr-2023 | ||
| US-20250034273-A1 | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | Inactive | 08-Oct-2021 | C07K16/30 |
Arbele Signals
Arbele Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hong Kong Science & Technology Parks | Accelerator/Incubator | Minority | ||
| AFCR | Not-For-Profit Venture Capital | |||
| HK Tech 300 | Accelerator/Incubator | Minority | ||
| AIM-HI | Accelerator/Incubator | Minority |
Arbele Investments (2)
Arbele’s most recent deal was a Joint Venture with Celvita. The deal was made on 09-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Celvita | 09-Feb-2023 | Joint Venture | Other Healthcare Services | ||
| Cellular Immunotherapy (Arbele/Avalon GloboCare) | 23-Oct-2018 | Joint Venture | Drug Discovery |
Arbele FAQs
-
When was Arbele founded?
Arbele was founded in 2016.
-
Where is Arbele headquartered?
Arbele is headquartered in Bellevue, WA.
-
What is the size of Arbele?
Arbele has 17 total employees.
-
What industry is Arbele in?
Arbele’s primary industry is Drug Discovery.
-
Is Arbele a private or public company?
Arbele is a Private company.
-
What is Arbele’s current revenue?
The current revenue for Arbele is .
-
How much funding has Arbele raised over time?
Arbele has raised $11.2M.
-
Who are Arbele’s investors?
Hong Kong Science & Technology Parks, AFCR, HK Tech 300, and AIM-HI have invested in Arbele.
-
Who are Arbele’s competitors?
TORL BioTherapeutics, Chimeric Therapeutics, Simcere, and Boehringer Ingelheim are competitors of Arbele.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process